US medical-equipment maker Danaher’s takeover of GE's biopharma unit has been approved by China's antitrust regulator, conditioned on a package of remedies including divestitures to mitigate the deal's impact on competition.Notably, Washington, DC-based Danaher is required to commit to a research and development project for at least two years as part of